Novartis Receives FDA Approval For Rhapsido To Treat Symptomatic Dermographism

Novartis has received FDA approval for Rhapsido (remibrutinib) as the first treatment for symptomatic dermographism (SD), expanding its application beyond chronic spontaneous urticaria (CSU). This approval marks a significant milestone for the company in addressing this condition. The stock ticker for Novartis is NVS.